faa tirzepatide FDA confirms shortage is still over, gives compounders a grace period F.D.A. Approves New Obesity Drug

As more studies are completed, there will likely be more data on how it compares to other forms of administration

Poor appetite and unexplained weight loss

Experimental data suggests that Lp-PLA 2 , rather than PON1, is the major HDL-associated hydrolase that is responsible for the hydrolysis of oxidized phospholipids

Executive Summary Written by Jonathan Wright, British Clinical Pharmacist Last reviewed: February 2026 Glucagon-like peptide-1 (GLP-1) receptor agonists including semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro) have transformed the treatment of obesity and type 2 diabetes

Personalized Medicine Approaches The development of biomarkers to predict tirzepatide response could enable more personalized treatment approaches